Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Carl Zeiss Meditec AG    AFX   DE0005313704

CARL ZEISS MEDITEC AG

(AFX)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 01/27 03:59:11 pm
130.7 EUR   -2.46%
01/21CARL ZEISS MEDITEC AG : DZ Bank drops its Sell rating
MD
01/20CARL ZEISS MEDITEC AG : Berenberg sticks Neutral
MD
01/20CARL ZEISS MEDITEC AG : Deutsche Bank reiterates its Buy rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Carl Zeiss Meditec : ZEISS Medical Technology Nominated for Deutscher Zukunftspreis 2020

09/11/2020 | 08:37am EST

ZEISS experts Dr.-Ing. Michelangelo Masini and Frank Seitzinger represent the ZEISS team and, together with Prof. Dr. med. Andreas Raabe from the Swiss Inselspital (University Hospital of Bern), have been nominated for the Deutscher Zukunftspreis 2020 (The Federal President's Award for Innovation and Technology).

Their project: The Robotic Visualization System - aka the KINEVO 900 from ZEISS - which improves the efficiency and effectiveness of surgical procedures. With this award, German President Frank-Walter Steinmeier honors those scientists and their innovations that unlock scientific potential and create jobs.

Nominated for the Deutscher Zukunftspreis 2020

Nominated for the Deutscher Zukunftspreis 2020 (from left to right): Dr.-Ing. Michelangelo Masini, Prof. Dr. med. Andreas Raabe and Frank Seitzinger, Picture: Deutscher Zukunftspreis / Ansgar Pudenz

An innovation ready for the future

ZEISS KINEVO 900 is a future-ready platform that is constantly being optimized and expanded. First technologies are already available today. Sharing images via streaming technologies and using AI algorithms to recognize patterns are just a few of the features that were recently made available. 'The continuous search for value-adding innovations is an important part of the ZEISS DNA,' says Dirk Brunner, Head of the Microsurgery strategic business unit.

Winners to be chosen on 25 November 2020

'We are delighted that a Carl Zeiss Meditec project has been nominated for this prestigious award,' says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG and Member of the Board at Carl Zeiss AG. 'This underscores our aspiration to create market-shaping innovations that improve patients' quality of life and help shape medical progress.' ZEISS is the first-ever company to have two candidates nominated for the Deutscher Zukunftspreis since the accolade was first bestowed back in 1997. Alongside Carl Zeiss Meditec, a team from the ZEISS Semiconductor Manufacturing Technology segment has also made the shortlist.

The nomination of Prof. Dr. med. Andreas Raabe, Dr. Michelangelo Masini and Frank Seitzinger was officially announced today 20 at the German Museum in Munich. The path to the nomination required passing a multi-stage selection process and selection by a distinguished jury. On 25 November 2020, the jury of the Federal President's Award for Innovation and Technology will decide which of the three nominated teams will take home the award.

Carl Zeiss Meditec's nominated project addresses demographic megatrends

We live in an aging society, which means ever more people will require medical treatment. Meanwhile, the population continues to grow - and an increasing number of people are gaining access to medical care. Healthcare systems across the world can only address this growing need if they become more efficient and more effective. Modern technologies like digitalization and artificial intelligence support healthcare providers as they administer these treatments. As does the ZEISS KINEVO 900, which is used in spinal and neurosurgery.

Comprising of more than 100 innovations and 180 patents, the system marries robotics, digital visualization and modern assistance solutions. The development team worked with global clinical partners to define and develop a 3-in-1 system that unifies microscopic, exoscopic and endoscopic components. Many institutions have recognized the benefits of the Robotic Visualization System to make surgical treatment more effective and more efficient. Since the ZEISS KINEVO 900 was launched in early 2017, it has been granted regulatory approval in more than 100 countries. It is used in over 300,000 surgical procedures every year.

The Robotic Visualization System KINEVO 900 from ZEISS

The Robotic Visualization System KINEVO 900 from ZEISS improves the efficiency and effectiveness of surgical procedures.

Press Contact

Sebastian Frericks

Director Investor Relations

Carl Zeiss Meditec AG

Phone: +49 3641 220-116

investors.meditec@zeiss.com

Petra Rettenmaier

Head of Communications, Visualization and Microsurgical Workplaces Carl Zeiss Meditec AG

Phone: +49 3641 220 331

press.med@zeiss.com

Brief Profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 3,232 employees (as of 30 September 2019) worldwide, the Group generated revenue of EUR1,459.3m in fiscal year 2018/19 (as of 30 September).

The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

For further information visit: www.zeiss.com/med

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about CARL ZEISS MEDITEC AG
01/21CARL ZEISS MEDITEC AG : DZ Bank drops its Sell rating
MD
01/20CARL ZEISS MEDITEC AG : Berenberg sticks Neutral
MD
01/20CARL ZEISS MEDITEC AG : Deutsche Bank reiterates its Buy rating
MD
01/19CARL ZEISS MEDITEC : Ad Hoc Announcement 19-Jan-2021
PU
01/19CARL ZEISS MEDITEC : achieves increase in profit in first quarter 2020/21
EQ
01/19DGAP-ADHOC : Carl Zeiss Meditec AG achieves increase in profit in first quarter ..
DJ
01/13OPTISCAN IMAGING : Receives Orders from Carl Zeiss Meditec; Shares Fall 4%
MT
2020DGAP-RPT : Carl Zeiss Meditec AG: Release according to Article 111c (4) of the A..
EQ
2020CARL ZEISS MEDITEC AG : Reduced to Neutral by NorldLB
MD
2020CARL ZEISS MEDITEC AG : UBS sticks Neutral
MD
More news
Financials
Sales 2021 1 507 M 1 825 M 1 825 M
Net income 2021 182 M 220 M 220 M
Net cash 2021 612 M 741 M 741 M
P/E ratio 2021 65,3x
Yield 2021 0,52%
Capitalization 11 699 M 14 151 M 14 166 M
EV / Sales 2021 7,36x
EV / Sales 2022 6,60x
Nbr of Employees 3 290
Free-Float 40,9%
Chart CARL ZEISS MEDITEC AG
Duration : Period :
Carl Zeiss Meditec AG Technical Analysis Chart | AFX | DE0005313704 | MarketScreener
Technical analysis trends CARL ZEISS MEDITEC AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 112,25 €
Last Close Price 130,80 €
Spread / Highest target 15,4%
Spread / Average Target -14,2%
Spread / Lowest Target -54,1%
EPS Revisions
Managers and Directors
NameTitle
Ludwin Monz President & Chief Executive Officer
Michael Kaschke Chairman-Supervisory Board
Justus Felix Wehmer Chief Financial Officer
Markus Guthoff Member-Supervisory Board
Christian Müller Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
CARL ZEISS MEDITEC AG23.05%14 577
THERMO FISHER SCIENTIFIC11.39%201 271
DANAHER CORPORATION5.33%166 214
INTUITIVE SURGICAL, INC.-5.92%90 477
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.14.55%85 238
ILLUMINA, INC.13.66%61 400